David Hoang
Stock Analyst at Deutsche Bank
(3.23)
# 1,082
Out of 5,090 analysts
47
Total ratings
51.35%
Success rate
2.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $29.30 | +53.61% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $191.83 | +45.96% | 2 | Oct 17, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $43 | $33.55 | +28.17% | 1 | Sep 26, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $38.25 | -5.88% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $22.81 | -47.39% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $26.59 | +31.65% | 5 | May 21, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $44.69 | +49.92% | 3 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $20.30 | +52.71% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $9.61 | +576.38% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $148.41 | +18.59% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $21.36 | -43.81% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $153.75 | +2.76% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.00 | +250.00% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.93 | +170.04% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.34 | +268.66% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $464.56 | -52.64% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $64.67 | +23.70% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $3.38 | -11.11% | 1 | Dec 7, 2022 |
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $29.30
Upside: +53.61%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $191.83
Upside: +45.96%
Spyre Therapeutics
Sep 26, 2025
Initiates: Buy
Price Target: $43
Current: $33.55
Upside: +28.17%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $38.25
Upside: -5.88%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $22.81
Upside: -47.39%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $26.59
Upside: +31.65%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $44.69
Upside: +49.92%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $20.30
Upside: +52.71%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $9.61
Upside: +576.38%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $148.41
Upside: +18.59%
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $21.36
Upside: -43.81%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $153.75
Upside: +2.76%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $2.00
Upside: +250.00%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $5.93
Upside: +170.04%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $4.34
Upside: +268.66%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $464.56
Upside: -52.64%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $64.67
Upside: +23.70%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $3.38
Upside: -11.11%